Peptide Monographs

CJC-1295 and Tesamorelin side by side

CJC-1295 and Tesamorelin are both indexed under GHRH analogues. Every cell below carries the record it came from, and an axis with no retrieved value reads Unknown rather than being filled by inference.

Summary

Both are modified GHRH analogues designed for longer action than the native 1-29 fragment. The cited 2006 Journal of Clinical Endocrinology and Metabolism paper reports prolonged growth hormone and IGF-I stimulation by CJC-1295, and the cited 2010 paper in the same journal reports tesamorelin, TH9507, as a growth hormone-releasing factor analogue.

[1, 2, 3, 4, 5]

Side by side

Curated comparison axes for CJC-1295 and Tesamorelin
AxisCJC-1295Tesamorelin
Reported mechanismA long-acting GHRH analogue that activates the GRF receptor; the retrieved literature attributes its extended duration of action to albumin bioconjugation.[8, 10]A growth hormone-releasing factor analogue acting at the GHRH receptor.[3]
Molecular formulaC165H269N47O46[6]C221H366N72O67S[11]
Molecular weight3647.2 g/mol[6]5136 g/mol[11]
FDA application registerA query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[7]A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including BLA022505, marketed as EGRIFTA). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[12]

Where the two literatures diverge

The retrieved literatures sit at different stages. Tesamorelin carries a clinical programme, including the cited 2008 long-term safety study and the 2014 JAMA and 2019 Lancet HIV papers on visceral and liver fat, and the Drugs@FDA register returned an application under its name. CJC-1295 has pharmacology and anti-doping identification records, including the cited 2010 paper identifying it in a sample, and no application record.

[1, 2, 3, 4, 5]

Where this page sits

Full pages: CJC-1295 and Tesamorelin.

Shared class: GHRH analogues.

Other pairs in the same class

All side-by-side pages: index.

Sources

  1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab (2006). pmid:16352683
  2. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal (2010). pmid:21204297
  3. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab (2010). pmid:20554713
  4. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS (2008). pmid:18690162
  5. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA (2014). pmid:25038357
  6. PubChem Compound Summary for CID 91971820, Cjc 1295. PubChem, National Library of Medicine (2026). pubchem:91971820
  7. Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:cjc-1295
  8. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology (2005). pmid:15817669
  9. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab (2006). pmid:17018654
  10. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res (2009). pmid:19386527
  11. PubChem Compound Summary for CID 16137828, Tesamorelin. PubChem, National Library of Medicine (2026). pubchem:16137828
  12. Drugs@FDA application register query for this compound, 1 application(s) returned: BLA022505. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:tesamorelin
  13. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr (2010). pmid:20101189
  14. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV (2019). pmid:31611038

On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.

Related resources